Prevalence of HCC among Living Donor Liver Transplant Recipients and Effect on Outcome Georgian Experience

75 38


  • Marika Mortuladze Batumi Shota Rustaveli State University
  • Sophio Beridze Avicenna-Batumi Medical University
  • Giorgi Kamkamidze University of Georgia
  • Kakhaber Kashibadze Batumi Shota Rustaveli State University



: Liver transplantation (LT) may be the best curative treatment that offers a chance of cure for the tumor and the underlying cirrhosis by complete extirpation of both. Hepatocellular Carcinoma (HCC) is a formidable global health challenge, representing one of the most prevalent primary liver malignancies with increasing incidence rates worldwide. It sets the stage for a comprehensive exploration of how LDLT has redefined the paradigms of treatment for HCC and contributed to enhanced patient outcomes. To answer the question of this paper we used cross sectional study design among 84 Living Donor Liver Transplant Recipients. After collecting data analyzing patient’s medical cards we have found that out of 84 recipients 12 (11%) had a Hepatocellular Carcinoma, out of this 8 (6.7%) recipients dead and 4 (3.3%) is alive. We may have challenges such as: Diagnostic Challenges, Treatment Options, and Selection Criteria for LDLT in HCC. The relationship between HCC and LDLT is a dynamic and evolving field. LDLT has significantly expanded the therapeutic options for selected HCC patients, offering hope for improved outcomes. However, the intricate interplay between patient selection, surgical techniques, and post-transplant care underscores the importance of a multidisciplinary approach to HCC management. Ongoing research and advances in both HCC treatment and LDLT continue to shape the landscape of this complex disease and transplantation strategy.  




How to Cite

Mortuladze, M., Beridze, S., Kamkamidze, G., & Kashibadze, K. (2023). Prevalence of HCC among Living Donor Liver Transplant Recipients and Effect on Outcome Georgian Experience. The Eurasia Proceedings of Health, Environment and Life Sciences, 12, 18–21.